Kobat Hasan, Elkonaissi Islam, Dorak Mehmet Tevfik, Nabhani-Gebara Shereen
Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Penrhyn Road, Kingston Upon Thames.
Pharmacy Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
Oncol Rev. 2021 Feb 26;15(1):510. doi: 10.4081/oncol.2021.510.
Cardiotoxicity induced by anti-cancer treatment has become a significant threat as the number of cardiotoxic anti-cancer agents is growing. Cancer patients are at an increased risk of contracting coronavirus disease 2019 (COVID-19) because of immune suppression caused by anti-cancer drugs and/or supportive treatment. Deterioration in lung functions due to COVID-19 is responsible for many cardiac events. The presence of COVID-19 and some of its treatment modalities may increase the chance of cardiotoxicity development in cancer patients receiving potentially cardiotoxic agents. This review provides evidence-based information on the cardiotoxicity risk in cancer patients clinically diagnosed with COVID-19 who are receiving potentially cardiotoxic anti-cancer agents. Proposed strategies relating to the management of this patient cohorts are also discussed.
随着具有心脏毒性的抗癌药物数量不断增加，抗癌治疗引起的心脏毒性已成为一个重大威胁。由于抗癌药物和/或支持性治疗导致的免疫抑制，癌症患者感染2019冠状病毒病（COVID-19）的风险增加。COVID-19导致的肺功能恶化是许多心脏事件的原因。COVID-19的存在及其一些治疗方式可能会增加接受潜在心脏毒性药物的癌症患者发生心脏毒性的几率。本综述提供了关于临床诊断为COVID-19且正在接受潜在心脏毒性抗癌药物的癌症患者心脏毒性风险的循证信息。还讨论了针对这一患者群体管理的建议策略。
